Biogen Aktie
WKN: 789617 / ISIN: US09062X1037
27.05.2025 13:55:34
|
Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies
(RTTNews) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies.
Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from Biogen.
The collaboration will initially focus on a single target that mediates key central nervous system diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines.
Biogen will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.
Under the terms of the agreement, City Therapeutics will receive a total of $46 million in payments including a $16 million upfront payment and an investment of $30 million in exchange for a City Therapeutics convertible note, representing a minority equity interest in the company if converted.
The upfront payment will be recorded by Biogen as an Acquired In-Process Research and Development expense in the second quarter of 2025.
Should the initial program achieve certain development and commercial milestones, City Therapeutics is eligible to receive up to approximately $1 billion in potential milestone payments plus tiered royalties in the high single-digit to low double-digit range based on net sales.
Biogen will have the option to select one additional target in the collaboration, subject to an additional payment and availability of the target.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
31.07.25 |
Freundlicher Handel in New York: NASDAQ 100 zum Start des Donnerstagshandels in Grün (finanzen.at) | |
31.07.25 |
Ausblick: Biogen zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
28.07.25 |
NASDAQ Composite Index-Papier Biogen-Aktie: So viel Verlust hätte ein Investment in Biogen von vor 3 Jahren eingebracht (finanzen.at) | |
28.07.25 |
Montagshandel in New York: NASDAQ 100 zum Handelsstart in Grün (finanzen.at) | |
21.07.25 |
NASDAQ-Handel: NASDAQ 100 zum Ende des Montagshandels in der Gewinnzone (finanzen.at) | |
21.07.25 |
Börse New York: NASDAQ 100 am Montagnachmittag freundlich (finanzen.at) | |
21.07.25 |
NASDAQ-Handel: NASDAQ Composite am Montagmittag mit Zuschlägen (finanzen.at) | |
21.07.25 |
Freundlicher Handel in New York: So entwickelt sich der S&P 500 am Mittag (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
Biogen Inc | 111,30 | -5,24% |
|